ABOUT THE DISORDER
Is a chronic progressive non-scarring alopecia. It typically presents thinning of the frontal, temporal, vertex scalp and deep recession of the fronto-temporal hairline. Hair thinning may lead to complete baldness in affected areas. It is the most common hair loss disorder affecting all men. The exact cause of MPHL is unknown and is likely multifactorial and may include genetic predisposition and follicular androgen sensitivity. Management includes anti-androgen (i.e. finasteride), minoxidil (oral/ topical), low level light therapy, platelet rich plasma, scalp camouflage (i.e. scalp micropigmentation, hair fibers, wigs), essential oils (i.e. rosemary), and nutritional supplementation.
– Panahi Y. et al.. Rosemary oil vs minoxidil 2% for the treatment of androgenetic alopecia: A randomized comparative trial. Skinmed. 2015;13(1):15-2
– Farris PK et al.. A Novel Multi-Targeting Approach to Treating Hair Loss, Using Standardized Nutraceuticals. J Drugs Dermatol. 2017 Nov 1;16(11):s141-s148
– Kanti V, et al. . Evidence-based (S3) guideline for the treatment of oandrogenetic alopecia in women and in men – short version. J Eur Acad Dermatol Venereol. 2018 Jan;32(1):11-22